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Stromal communication with cancer cells can in-
fluence treatment response. We show that stromal
and breast cancer (BrCa) cells utilize paracrine and
juxtacrine signaling to drive chemotherapy and radi-
ation resistance. Upon heterotypic interaction, exo-
somes are transferred from stromal to BrCa cells.
RNA within exosomes, which are largely noncoding
transcripts and transposable elements, stimulates
the pattern recognition receptor RIG-I to activate
STAT1-dependent antiviral signaling. In parallel, stro-
mal cells also activate NOTCH3 on BrCa cells. The
paracrine antiviral and juxtacrine NOTCH3 pathways
converge as STAT1 facilitates transcriptional re-
sponses to NOTCH3 and expands therapy-resistant
tumor-initiating cells. Primary human and/or mouse
BrCa analysis support the role of antiviral/NOTCH3
pathways in NOTCH signaling and stroma-mediated
resistance, which is abrogated by combination ther-
apy with gamma secretase inhibitors. Thus, stromal
cells orchestrate an intricate crosstalk with BrCa
cells by utilizing exosomes to instigate antiviral sig-
naling. This expands BrCa subpopulations adept at
resisting therapy and reinitiating tumor growth.
INTRODUCTION
The elucidation of resistance mechanisms to chemotherapy and
radiation is an important goal in improving cancer survival. Pre-viously, we characterized a gene signature for radiation (RT)
and chemotherapy (chemo) resistance that was discovered
through in vivo selection for RT-resistant tumors (Khodarev
et al., 2004; Weichselbaum et al., 2008). Because the majority
of the genes identified were interferon-stimulated genes (ISGs),
which normally are activated as part of an antiviral response,
we termed this signature the interferon-related DNA damage
resistance signature (IRDS). Several IRDS genes, including the
transcription factor STAT1, influence RT/chemo resistance in
cell lines and mouse tumor models. Interrogation across the
most common human cancers revealed that a large proportion
of untreated primary tumors express the IRDS. In breast cancer,
IRDS expression measured by a clinical classifier comprised of
seven IRDS genes (STAT1, MX1, ISG15, OAS1, IFIT1, IFIT3,
and IFI44) identifies patients whose cancers are resistant to
chemo and RT. Thus, the IRDS may represent a common and
inherent mechanism of resistance across various human can-
cers. How the IRDS is regulated and how ISGs can protect
against RT/chemo is unclear.
A common way that ISGs are activated is through pattern
recognition receptors (PRRs) that are triggered by pathogen-
associated molecular patterns such as viral nucleic acids (Loo
and Gale, 2011). PRRs include toll-like receptors (TLRs) and
RIG-I-like receptors. Typically, RIG-I is activated by 50-triphos-
phate viral RNA after viruses gain entry into immune and non-
immune cells. However, PRRs can also be activated through
alternative routes by exosomes, which are small membrane ves-
icles capable of transferring contents between cells to function in
cell-cell communication (The´ry et al., 2009). Exosomes can
transfer viral RNA from infected cells to trigger an interferon
response in immune cells, presumably through TLRs, to enhance
viral suppression (Dreux et al., 2012; Li et al., 2013b). In cancer,Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 499
exosomes secreted by tumor cells can increase metastasis
through interaction with cells of the microenvironment (Fabbri
et al., 2012; Peinado et al., 2012). Alternatively, exosomes from
mesenchymal cells can be transferred to cancer to promote
metastasis (Luga et al., 2012). Thus, these recent data suggest
that PRRs and exosomes orchestrate heterotypic cell-cell
communication to regulate antiviral responses or to aid cancer
progression. Whether crosstalk between cancer and the tumor
microenvironment can use exosomes and PRRs to similarly con-
trol ISG/IRDS expression or influence treatment resistance is
unknown.
The importance of the tumor microenvironment in dictating
treatment response is increasingly evident. Stromal cells, which
are primarily fibroblasts but can also be other cell types, can pro-
mote survival after genotoxic and targeted therapy through the
secretion of paracrine factors (McMillin et al., 2013). Many of
these interactions between stromal cells and tumor cells may
support the maintenance of cancer stem-like cells (i.e., tumor-
initiating cells) analogously to how normal stem cells depend
on a niche (Korkaya et al., 2011). Because tumor-initiating cells
are resistant to RT/chemo and their survival would allow efficient
tumor regrowth, understanding how the stromal microenviron-
ment can influence these therapy resistant cells may provide
promising new drug targets.
The NOTCH family of receptors activates developmental
signaling pathways that have multiple roles in cancer, including
drug resistance (McAuliffe et al., 2012; Ranganathan et al., 2011)
and the regulation of tumor-initiating cells (Azzam et al., 2013).
Activation requires cell-cell contact and engagement of NOTCH
ligands, such as JAGGED proteins. Given the properties of the
NOTCH pathway in cancer, there is a significant interest in target-
ing the pathway as a cancer therapeutic. Activation of NOTCH
occurs through the cleavage of its intracellular domain and can
be blocked by a gamma secretase inhibitor (GSI). Currently, there
are multiple clinical trials testing GSIs combined with other tar-
geted agents and conventional chemotherapy (Aster and Black-
low, 2012). However, challenges exist that include lack of a
companion biomarker to identify patients who will benefit from
NOTCH inhibition. Understanding how NOTCH can be activated
in subsets of cancersmay facilitate their utilization as drug targets.
In this study, we integrate experimental and computational
models to investigate how stromal cells communicate with
breast cancer to regulate expression of ISGs. In so doing, we
define an antiviral pathway that is activated by exosomes and
RIG-I and cooperates with NOTCH3 to regulate stroma-medi-
ated expansion of therapy-resistant cells.
RESULTS
Stromal Cells Induce the IRDS and Increase Breast
Cancer Radiation Resistance
Previous reports indicate that ISGs can be modulated by the
microenvironment (Buess et al., 2007). To examine whether the
microenvironment can influence IRDS expression and contribute
to RT/chemo resistance, we utilized metastatic MDA-MB-231
breast cancer cells (1833) (Kang et al., 2003) expressing a
GFP-luciferase reporter and xenografted them with or without
nontransformed MRC5 human diploid fibroblasts used as stro-500 Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc.mal cells. Tumors containing admixed fibroblasts exhibited
high expression of several IRDS genes, including STAT1 (Fig-
ure 1A), particularly from breast cancer cells (Figure 1B). In
contrast, tumors arising from breast cancer cells alone had lower
STAT1/ISG expression and remained primarily comprised of
human breast cancer cells, suggesting poor stromalization by
mouse cells. The presence of admixed fibroblasts enhanced
the growth rate of breast cancer cells (Figure 1C), which is a
defining property of carcinoma-associated fibroblasts (CAFs),
as measured by the rate of change in bioluminescence signal
at each time point. After RT, breast cancer cells from tumors
without admixed fibroblasts promptly stopped growing and
showed regression by day 24. In contrast, breast cancer ad-
mixed with fibroblasts showed dramatically reduced cell death
(Figure 1D) and maintained significant growth even after RT (Fig-
ure 1C). In total, these observations suggest a relationship
between tumor and stromal cell interaction, antiviral signaling,
and survival of cells adept at resisting DNA damage and sustain-
ing tumor growth.
Stroma-Mediated IRDS Induction and Protection
Are STAT1 Dependent and Specific for Basal-like
Breast Cancers
To better examine the relationship between IRDS expression
and stroma-mediated protection across different breast cancer
and stromal cell combinations, we cocultured both cell types
in vitro to model stroma-mediated resistance (referred to as
coculture) and discovered that breast cancer cells can be
divided into two groups. The first group, called ‘‘IRDS re-
sponders’’ (IRDS-Rs), is enriched in the basal-like subtype (Table
S1 available online) and upregulated IRDS genes after interac-
tion with MRC5 fibroblasts (Figure 1E). The second group, called
‘‘IRDS nonresponders’’ (IRDS-NRs), is composed of non-basal-
like and some basal-like subtypes and failed to induce IRDS
genes. Importantly, only IRDS-Rs were protected by fibroblasts
after RT (Figure 1F) or after chemotherapy (Figure 1G). Multiple
other stromal cell lines (CAFs, bone marrow, and fibroblasts)
able to induce the IRDS were also able to promote resistance
against RT (Figure S1A); however, not all stromal cells were pro-
tective, as illustrated by a macrophage cell line that neither
induced the IRDS nor protected (Figure S1B). Genome-wide
transcriptomic analysis from coculture of IRDS-R compared to
monoculture (Table S1) demonstrated upregulation of nearly all
IRDS genes in breast cancer (Figures 1H and S1C and Table
S2). Stroma-mediated induction of IRDS was specific to IRDS-
R breast cancer (Table S3). Knockdown of STAT1 in 1833
IRDS-R prior to coculture with MRC5 fibroblasts depressed
nearly all IRDS genes compared to control (Figure 1H) and also
inhibited stroma-mediated resistance (Figure 1I), a result
observed with multiple different siRNAs targeting STAT1 (Fig-
ures S1D and S1E). Stable STAT1 knockdown (Figures S1D
and S1E) also selectively inhibited the protective effects of
MRC5 fibroblasts as measured by an in vitro luciferase-based
assay (Figure 1J). In the absence of RT, disruption of STAT1
had negligible effects on growth with or without fibroblasts (Fig-
ure S1F). Thus, a subset of basal subtype breast cancers can
interact with multiple stromal cell types to increase IRDS genes
and RT/chemo resistance in a STAT1-dependent manner.
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Figure 1. Stromal Cells Induce ISGs and Protect Basal-like Breast Cancer Cells against Radiation in a STAT1-Dependent Manner
(A) Human MDA-MB-231 metastatic breast cancer cell (BrCa) line (1833) was admixed with or without MRC5 normal human fibroblasts (stroma), and expression
of IRDS genes was determined by qRT-PCR.
(B) GFP-labeled 1833 breast cancer cells with and without MRC5 fibroblasts were xenografted subcutaneously into nudemice, and tumors were imaged (203) at
day 14. STAT1 intensity in breast cancer cells is quantitated for representative field shown. Scale bar, 100 microns.
(C) Bioluminescence imaging (BLI) response of 1833 breast cancer cells with a luciferase reporter gene after xenografting with and without MRC5 fibroblasts.
Tumors were irradiated with 8 Gy (day 0). Shown is change in photon flux over time (first derivative, mean ± SEM, n = 5–10). Positive first derivative indicates
growth, zero indicates no growth, and negative values denote regression. Data are a separate analysis of the control groups from Figure 5M.
(D) 1833 breast cancer cells were stained with GFP and TUNEL (red) 10 days after RT. Percent TUNEL positive is shown. Scale bar, 100 microns.
(E) Breast cancer cells (Table S1) were classified as IRDS responders (IRDS-Rs) or IRDS nonresponders (IRDS-NRs). Heat map and scale show breast cancer
IRDS genes after monoculture (M) or MRC5 coculture (C).
(F) Cell death of IRDS-Rs and IRDS-NRs 4 days after 10 Gy RT in mono- (Mono) and coculture (Co-cx) (n = 3–10).
(G) Cell death of 1833 IRDS-R after cisplatin chemotherapy (n = 3) and after dose response.
(H) Gene Set Analysis shows changes in IRDS genes 48 hr after coculture versus monoculture of IRDS-Rs (left; also see Table S1) or after STAT1 knockdown in
1833 IRDS-R in coculture (right). Top graph plots individual and overall gene scores, and bottom graph shows fold change.
(I) Cell death of 1833 IRDS-R 4 days after 10 Gy RT using three independent siRNAs to STAT1.
(J) BLI-based survival assay after 10 Gy RT (day 0) using luciferase-labeled 1833 cells with shSTAT1 or control knockdown (shCont). Photon flux (3106) for each
well is indicated. Shown is representative experiment (n = 5). *p < 0.05.
Unless noted, all bar plots in figure are mean ± SD of n biological replicates. See also Figure S1.IRDS Induction Is Controlled by RIG-I
Stroma-mediated IRDS induction and resistance requires live
stromal cells and does not associate with expression and/or
function of interferons or interferon receptors (Figures S2A–S2E). To explore alternative pathways to IRDS induction, we
examined the transcriptome of IRDS-R breast cancer cells in
MRC5 coculture compared to monoculture. Among the upregu-
lated genes (Table S2) were several PRRs known to activateCell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 501
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Figure 2. Stromal Cell Interaction Increases Exosomes that Upregulate ISGs through a RIG-I Antiviral Pathway
(A) Importance scores (higher is more predictive) of PRRs from amultivariable RF regression model to predict induction of IRDS after MRC5 coculture with IRDS-
Rs. The model explains 60.8% of the total variance. Adjusted effect of RIG-I on IRDS metagene expression is shown on right (red dashes are ± 2 SE).
(B) Expression of IRDS genes after siRNA to RIG-I (top row) or MYD88 (bottom row) in 1833 IRDS-R. Shown is a representative experiment (n = 3).
(C) Cell death of 1833 IRDS-R after RT (n = 4) and a representative BLI-based survival assay (n = 2) after the indicated knockdown (RT on day 0). Photon flux (3106)
for each well is shown. The control is same as Figure 1J.
(D) Expression of IRDS genes in 1833 IRDS-R (middle) or MCF7 IRDS-NR (right) after addition of conditionedmedia (CM) fromMRC5 fibroblasts (Stroma), IRDS-R
or IRDS-NR (BrCa), or MRC5 coculture with IRDS-Rs or IRDS-NRs (co-cx). See schematic (left).
(E) CM collected after 48 hr or the soluble fraction from CM (soluble) was applied to 1833 IRDS-R, and expression of IRDS genes was examined (n = 4).
(F) Fold induction of IRDS genes in 1833 IRDS-R after addition of coculture CM or purified exosomes (n = 5).
(G) NanoSight quantification of exosomes (left) from 1833 IRDS-R, MRC5 fibroblasts (Stroma), andMRC5 coculture using either 1833 IRDS-R or IRDS-NR (MDA-
MB-468, IRDS-NR_1; MCF7, IRDS-NR_2). Immunoblot for TSG101 (right) using 1833 IRDS-R or IRDS-NR (MDA-MB-468, lanes 4–5; MCF7, lanes 6–7).
(H) MRC5 fibroblasts (stroma) or 1833 IRDS-R were labeled with green or red lipophilic dye in monoculture (left and middle). For coculture (right), MRC5 (arrows)
were labeled red, and breast cancer cells were labeled green. Scale bar, 40 microns.
(I) Representative flow cytometry of DiD dye transfer from MRC5 stroma to 1833 IRDS-R or MDA-MB-468 IRDS-NR.
(J) Exosome transfer from coculture after TSG101 knockdown (left) and after addition of the coculture CM cleared of debris and apoptotic bodies (right) (n = 4).
(K) IRDS gene induction by coculture CM after TSG101 knockdown in 1833 IRDS-R, MRC5 stroma, or both (n = 3). Gene expression and significance levels are
relative to siControl. *p < 0.05.
Unless noted, all bar plots in figure are mean ± SD of n biological replicates. See also Figure S2.ISGs. Random forest (RF) multivariable regression analysis
(Chen and Ishwaran, 2012) of these and other similar PRRs
demonstrated that increasing expression of RIG-I best explains
the upregulation of IRDS genes by fibroblasts (Figure 2A).
Accordingly, knockdown of RIG-I in 1833 IRDS-R inhibited502 Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc.IRDS gene induction after coculture, whereas disruption of
MYD88, which is required for signaling by multiple TLRs not
predicted to regulate the IRDS, had no effect (Figures 2B and
S2F). Disruption of RIG-I by shRNA (Figure S2F) also partially re-
versed stroma-mediated resistance, as measured by short- and
long-term survival (Figure 2C), without influencing general cell
proliferation (Figure S2G). Concomitant disruption of the type
one interferon receptor with RIG-I had no additive effect. Thus,
STAT1/IRDS induction and stromal protection are primarily initi-
ated through RIG-I rather than interferon receptors.
Exosomes Are Transferred from Stromal Cells to Breast
Cancer to Increase IRDS
Conditioned media (CM) from coculture of IRDS-Rs with stromal
fibroblasts, but not from stromal coculture of IRDS-NRs or from
monoculture, upregulate IRDS genes when applied to monocul-
tured IRDS-Rs (Figure 2D). Interestingly, CM from coculture of
IRDS-Rs also upregulates IRDS when applied to IRDS-NRs.
These results suggest that stromal cell interaction with IRDS-
Rs produces a secreted factor capable of activating RIG-I.
Recent evidence suggests that some PRRs can be activated
by exosomes. Consistent with a role for exosomes in IRDS acti-
vation, the exosome-depleted soluble fraction of CM poorly
induced the IRDS (Figure 2E). Conversely, addition of purified
exosomes, which were confirmed by electron microscopy and
by analyses of size properties and markers (Figure S2H), was
sufficient to induce IRDS genes (Figure 2F).
To examine how coculture with IRDS-Rs influences exosome
secretion and possible transfer to breast cancer cells, exosomes
were quantified by particle counting and by the exosomemarker
TSG101. Bothmethods indicated that more exosomeswere pre-
sent after coculture of IRDS-Rs compared to either IRDS-NRs or
monoculture (Figure 2G). To examine exosome transfer, stromal
cells and/or breast cancer cells were differentially labeled with
either red or green fluorescent lipophilic dye to mark exosomes.
For both cell types, dye transfer in monoculture appeared mini-
mal (Figure 2H). In coculture, microscopy and flow cytometry
revealed an apparent unidirectional transfer of exosomes from fi-
broblasts preferentially to IRDS-Rs, but not to IRDS-NRs (Fig-
ures 2H, 2I, S2I, and S2J). Multiple stromal cell types capable
of inducing the IRDS were also able to transfer exosomes to
IRDS-Rs (Figure S2K). Transfer was also observed upon addition
of coculture CM cleared of debris and apoptotic bodies (Fig-
ure 2J). With both assays, transfer was mitigated by knockdown
of TSG101 (Figures 2J and S3C), which is a regulator of exosome
biogenesis. Accordingly, TSG101 disruption in fibroblasts, but
not in breast cancer cells, also inhibited IRDS induction without
affecting elevation in non-IRDS genes such as MMP1 and
CXCL1 (Figures 2K and S3D). Thus, IRDS-Rs, but not IRDS-
NRs, coerce an increase in secretion of exosomes by stromal
cells that results in transfer to breast cancer cells and subse-
quent IRDS induction.
Exosome Transfer Is Regulated by Stromal RAB27B
To determine whether the increased production of exosomes in
coculture primarily originated from stromal or breast cancer
cells, we used a protein array of well-known exosome markers.
This revealed that coculture exosomes were much more similar
to exosomes from fibroblasts compared to those from breast
cancer cells (Figure 3A), arguing that enhanced exosome pro-
duction in coculture is primarily from stromal cells. Interrogation
of stromal RAB GTPases commonly implicated in exosome
secretion (Raposo and Stoorvogel, 2013) revealed that stromalRAB27B transcript and protein were consistently induced after
fibroblasts were cocultured with IRDS-Rs, but not with IRDS-
NRs (Figures 3B andS3A). Indeed, of all RABGTPases on themi-
croarray, RAB27B was elevated the most in fibroblasts after
interaction specifically with IRDS-Rs (Figure S3B). Knockdown
of RAB27B in fibroblasts (Figure S3C) inhibited the ability of
CM from coculture to stimulate IRDS genes (Figure 3C) but
had no effect on non-IRDS genes such as MMP1 and CXCL1
(Figure S3D). Accordingly, knockdown of RAB27B also inter-
fered with exosome transfer from fibroblasts to IRDS-Rs (Fig-
ure 3D), a result observed with multiple siRNAs to RAB27B
(Figure S3E). In contrast, inhibition of RAB27A, which was not
differentially expressed in fibroblasts, had no effect (Figure S3F).
In total, these data argue that exosome transfer from stromal to
breast cancer cells and subsequent IRDS induction is regulated
by stromal RAB27B.
50-Triphosphate Exosome RNA Activates RIG-I to
Induce the IRDS
Because exosomes and RIG-I both influence the effects of stro-
mal cells, we focused on a potential relationship between the
two. When RIG-I was disrupted in 1833 IRDS-R, IRDS gene in-
duction by coculture CM and by purified exosomes was similarly
inhibited (Figures 3E and 3F). RIG-I activation typically results
from binding to viral RNA through recognition of specific motifs
such as 50-triphosphates rather than through sequence speci-
ficity (Loo and Gale, 2011). To investigate whether exosome
RNA (exoRNA) can induce IRDS through RIG-I, exoRNA from
coculture exosomes was re-encapsulated into synthetic lipid
vesicles and transfected into monoculture 1833 IRDS-R.
Whereas total cellular RNA from coculture failed to induce
IRDS genes, exoRNA upregulated IRDS genes in a RIG-I-depen-
dent manner to levels that were comparable to a viral HCV RNA
used as a positive control (Figure 3G). In contrast, HCV RNA or
exoRNA did not significantly increase non-IRDS genes such as
IFI16, which normally responds to cytosolic DNA. Treatment
with RNase, but not DNase, eliminated the ability of exoRNA,
as well as an in-vitro-transcribed 50-triphosphate control RNA
(IVT50ppp), to elevate IRDS genes (Figure 3H). Removal of
50-phosphates revealed that the active RNA contains exposed
50-phosphate ends and is not a typical protein-coding mRNA
with a 50-cap (Figure 3I). Consistent with the known specificity
of RIG-I for 50-triphosphate, IRDS induction was inhibited after
specific removal of 50-triphosphate from exoRNA or from the
IVT50ppp, whereas digestion of RNA containing 50-monophos-
phate had no effect. Thus, exoRNA containing 50-triphosphate
activates RIG-I to induce IRDS genes.
Sequencing of exoRNA isolated from coculture of 1833 IRDS-
R revealed no apparent match to viral genomes from 19 different
viruses known to activate RIG-I. Instead, enrichment for human
intergenic and noncoding transcripts was observed in exoRNA
compared to total cellular RNA from coculture (Figure 3J). In
both cellular RNA and exoRNA, repetitive sequences accounted
for a significant fraction of these intergenic transcripts; however,
although snRNA-like repeats were the predominant class of re-
petitive elements in cellular RNA, transposable elements repre-
sented the largest class within exoRNA. Specifically, SINEs,
LINEs, and long terminal repeat (LTR) retrotransposons wereCell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 503
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Figure 3. Stromal Exosomes Are Regulated by RAB27B and Transfer 50-Triphosphate RNA to Activate RIG-I in Breast Cancer Cells
(A) Exosomes were isolated from monoculture of MRC5 fibroblasts (Stroma) or 1833 IRDS-R (right) or from coculture (left) and profiled by antibody array for the
indicated exosome markers. GM130 is a check for cellular contamination. Positive (+) and negative () controls are labeled.
(B) Averaged microarray expression of the indicated RABs from MRC5 in monoculture (stroma) or after coculture with IRDS-R or IRDS-NR are shown as a heat
map. Immunoblot (right) for RAB27B protein expression in MRC5 after coculture with MDA-MB-157 or 1833 IRDS-R (Figure S3A) compared to MRC5
monoculture.
(C) IRDS expression in 1833 IRDS-R after addition of CM isolated from coculture using MRC5 transfected with siRAB27B compared to siControl (n = 3).
(D) Exosome transfer to 1833 IRDS-R after coculture with or without RAB27B knockdown (left) or addition of coculture CM cleared of debris and apoptotic bodies
(right).
(E) Average IRDS gene expression (mean expression of IFIT1,MX1, and STAT1) in response to exosomes (Exo, n = 5) or coculture CM (n = 6) plotted againstRIG-I
levels after knockdown in 1833 IRDS-R.
(F) IRDS gene expression from two representative data points used to generate plot in Figure 3E are shown relative to siControl.
(G) IRDS gene expression after RNA from exosomes (ExoRNA), cellular RNA, or a positive control HCV RNA was transfected into 1833 IRDS-R with or without
RIG-I knockdown (n = 4). IFI16 is a non-IRDS gene used as a negative control.
(H and I) (H) Expression of IRDS genes IFIT1 andMX1 resulting from transfection of ExoRNA after RNase treatment or (I) removal of 50-monophosphate (50-p) and/
or 50-triphosphate (50-ppp) (n = 3). An in-vitro-transcribed 50-ppp RNA (IVT50ppp) is used as a positive control. Shown are RNA motifs remaining after enzyme
modification with alkaline phosphatase (AlkPase), Terminator exonuclease (Term), and tobacco acid pyrophosphatase (TAP). IVT50ppp serves as a control for
RNA enzyme modification by AlkPase and TAP.
(J) Distribution of known gene transcripts and intergenic transcripts from rRNA-depleted exoRNA and cellular RNA from 1833 IRDS-R coculture (left). Distribution
of major repetitive elements and transposable element classes for intergenic transcripts are shown on right.
(K) ExoRNA enrichment for major subfamilies of transposable elements and satellite sequences compared to cellular RNA. *p < 0.05.
Unless noted, all bar plots in figure are mean ± SD of n biological replicates. See also Figure S3.markedly enriched among exoRNA repetitive elements, with
the most prevalent subclasses augmented by 10-fold or more
(Figure 3K). Other repetitive sequences such as telomeric and504 Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc.centromeric satellite sequences were present at lower fre-
quencies but demonstrated 100- to 1,000-fold enrichment in
exoRNA. Because transposable elements are one category of
RNA polymerase III transcripts, which can have 50-triphosphate
ends (Belancio et al., 2010; Dieci et al., 2013), their enrichment
suggests that they may contribute to exoRNAs capable of stim-
ulating RIG-I.
Stroma-Mediated Paracrine Antiviral Signaling and
Juxtracrine NOTCH3 Signaling Enhance Transcription
of NOTCH Target Genes
Although RIG-I and STAT1 are necessary for stroma-mediated
resistance, separation of breast cancer cells from stromal fi-
broblasts using a transwell filter large enough for exosome
passage resulted in retained IRDS induction but loss of RT
resistance (Figure 4A). This suggests that the antiviral
pathway may work with an additional juxtacrine pathway to
control stroma-mediated protection. To explore this, we
computationally constructed a juxtacrine interactome be-
tween IRDS-Rs and fibroblasts using differentially expressed
genes from each cell type combined with protein-protein
interaction data (Figure S4A). This revealed that NOTCH3
expression was increased in IRDS-R breast cancer cells after
coculture, and its membrane-bound ligand JAG1 was both
induced in fibroblasts and constitutively elevated in IRDS-
Rs. Protein analysis confirmed that NOTCH3 was expressed
at low levels in 1833 IRDS-R, but both its expression and its
cleaved intracellular domain increased after fibroblast interac-
tion (Figure 4B). In contrast, expression of NOTCH1, 2, and 4
did not change.
To investigate how antiviral signaling and NOTCH3 might
interact, we explored whether STAT1 facilitates transcription
of NOTCH-dependent genes. Gene set enrichment analysis of
NOTCH target genes, which we defined by GSI washout exper-
iments (Table S4), confirmed upregulation of NOTCH targets in
IRDS-Rs, but not IRDS-NRs after coculture (Figure 4C). Knock-
down of STAT1 not only inhibited stroma-mediated upregulation
of NOTCH target mRNAs (Figure 4D) but also blunted the pri-
mary transcripts for canonical NOTCH targets HES1 and
HEY1 (Figure 4E), which is consistent with STAT1 exerting tran-
scriptional control over these genes. To better characterize this,
we utilized doxycycline inducible NOTCH3 intracellular domain
(NICD3) to constitutively activate NOTCH3 in 1833 IRDS-R
and added exosome-containing CM to initiate antiviral
signaling. As measured by the HEY1 primary transcript, CM
augmented responsiveness to NICD3 (Figure 4F). Depletion of
exosomes from CM inhibited this effect on the HEY1 primary
transcript (Figure 4G) and mRNA (Figure S4B), and similar re-
sults were noted for HES1. The exosome-dependent increase
in HEY1 and HES1 transcripts in the absence of NICD3 induc-
tion is likely due to baseline NOTCH and/or leakiness of the
inducible system.
Interrogation of ENCODE data revealed STAT1 occupancy
at several locations within active proximal promoters of multi-
ple NOTCH targets, including HEY1 and HES1 (Figures 4H
and S4C). Chromatin immunoprecipitation (ChIP) for STAT1
demonstrated that activation of antiviral signaling by CM or
by coculture increased STAT1 occupancy in the HEY1 pro-
moter, particularly between the transcriptional start site (TSS)
and 2kb where the ENCODE data were the most significant
(Figure 4H). STAT1 ChIP analysis for HES1 was similar (Fig-ure S4C). Despite high constitutive NICD3, knockdown of
STAT1 in 1833 IRDS-R decreased primary transcript and
mRNA levels for HES1 and HEY1 after activation of antiviral
signaling, which is consistent with the functional importance
of at least some of the STAT1 sites in cooperating with
NICD3 (Figure 4I). In contrast, although NOTCH3 itself is a
NOTCH target (Table S4), the proximal promoter of NOTCH3
appears devoid of STAT1 sites by ENCODE. Accordingly, CM
had no effect on the NOTCH3 primary transcript (Figure S4D),
suggesting that STAT1 affects transcription of NOTCH targets,
rather than the NOTCH3 gene. Thus, paracrine-activated
STAT1 can cooperate with juxtacrine-activated NOTCH3 to
augment the transcriptional response of multiple NOTCH
targets.
STAT1 and NOTCH3 Control Stroma-Mediated
Resistance through the Expansion of Therapy-Resistant
Breast Cancer Cells
Both antiviral and NOTCH signaling have roles in controlling
normal and cancer stem cells (Baldridge et al., 2010; Rangana-
than et al., 2011). Indeed, NOTCH and its target genes were
previously shown to help maintain a subpopulation of CD44+
CD24low+ cells that have tumor-initiating properties (e.g.,
increased mammosphere and tumor formation) (Azzam et al.,
2013). Because tumor-initiating cells (TICs) are known to be resis-
tant to RT/chemo, we investigated whether stromal cell interac-
tion might lead to the expansion of such therapy-resistant cells
(TRCs). Indeed, coculture resulted in the upregulation of a gene
signature associated with TICs (Shipitsin et al., 2007) (Figure 5A)
and in the expansion of the CD44+CD24low+ subpopulation of
1833 IRDS-R (Figure 5B). This CD44+CD24low+ population is
resistant to both RT and chemotherapy compared to CD44+
CD24neg counterparts (Figure 5C) and enriches after genotoxic
damage (Figure S5A). Coculture with fibroblasts prior to seeding
increased mammosphere formation (Figure 5D), and knockdown
of STAT1 or inhibition ofNOTCH3with either RNAi orGSI inhibited
both mammosphere formation (Figure 5E) and enhancement of
the TIC gene signature (Figure 5A). Similar STAT1-dependent
stromal cell activation of NOTCH3 and expansion of mammo-
spheres were observed in other IRDS-Rs as well (Figures S5B–
S5D). Constitutive activation of NOTCH3 in monoculture also
led to modest expansion of both mammospheres and CD44+
CD24low+ cells (Figures 5F and S5E). In accordance with an
expansion of CD44+CD24low+ TRCs, the proportion of surviving
mammospheres was higher after irradiation of cells seeded
fromcoculture compared tomonoculture (Figure 5G). Thus, these
results suggest that STAT1 and NOTCH3 can drive expansion of
breast cancer TRCs.
Like with STAT1, knockdown of NOTCH3 with multiple
different siRNAs inhibited both stroma-mediated expansion of
breast cancer TRCs and resistance (Figures 5H, S5F, and
S5G). Inhibiting JAG1 also inhibited RT resistance after cocul-
ture with the greatest effect occurring after disruption in both
1833 IRDS-R and fibroblasts (Figures 5I and S5H), which is
consistent with the interactome results showing JAG1 upregula-
tion in both cell types. Expression of NICD3 in monoculture
1833 IRDS-R partially recapitulated the protective effect of stro-
mal cells (Figure 5J). Similarly, ectopic NICD3 partially rescuedCell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 505
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Figure 4. STAT1 Enhances the Transcriptional Response to Juxtacrine NOTCH3 Signaling that Is Required for Stroma-Mediated Protection
(A) Cell death of 1833 IRDS-R in coculture after RT. MRC5 fibroblasts were separated by a transwell filter large enough to allow exosome passage (n = 3).
(B) Immunoblot of the indicated NOTCH family members in 1833 IRDS-R after monoculture (M) or coculture (C). Arrow indicates cleaved intracellular domain.
(C and D) (C) Expression of NOTCH target genes in IRDS-R and IRDS-NR after coculture and (D) after STAT1 knockdown in 1833 IRDS-R after coculture. NOTCH
targets were experimentally defined by GSI washout (Table S4) and were used in Gene Set Analysis.
(E) Expression of the indicated NOTCH target gene primary transcript (PT) in 1833 IRDS-R (n = 3).
(F) Expression ofHEY1 PT in response to doxcycyline (Dox)-induced NICD3 in 1833 IRDS-R with or without addition of coculture CM (mean ±SEM, n = 6–8). Inset
shows NICD3 levels after Dox addition (mg/ml).
(G) Expression of the indicated primary transcripts to NICD3 after addition of coculture CMor CMdepleted of exosomes (Exo dep). CM compared to CMdepleted
of exosomes is used for significance levels (mean ± SEM, n = 4–6).
(H) ENCODE ChIP data for STAT1 occupancy of the HEY1 proximal promoter region is shown along the indicated genomic coordinates. Bar plots show STAT1
ChIP from 1833 IRDS-R with and without addition of CM (left) and after mono- or coculture (right). Relative position upstream of the TSS is labeled on the x axis for
each bar plot. Shown are two representative experiments (mean ± SD) out of four total.
(I) Expression of HEY1 and HES1 mRNA or primary transcripts in response to NICD3 and coculture CM in 1833 IRDS-R with and without STAT1 knockdown
(mean ± SEM, n = 4–7). dp < 0.10 and *p < 0.05.
Unless noted, all bar plots in figure are mean ± SD of n biological replicates. See also Figure S4.the effect of STAT1 knockdown on stromal cell protection (Fig-
ure 5K). These partial effects on resistance parallel the partial
transcriptional responses of NOTCH target genes when only
STAT1 or NOTCH3 were fully engaged. Together, these data
suggest that stroma-mediated resistance results from coopera-
tion between STAT1 and NOTCH3 to expand and/or maintain
breast cancer TRCs.506 Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc.NOTCH Inhibition Reverses Stroma-Mediated
Resistance of IRDS Responders and Improves Survival
In Vivo
Considering that the NOTCH3 and STAT1 pathways are neces-
sary for stroma-mediated resistance in IRDS-Rs, we investi-
gated whether a GSI could selectivity reverse the protective
effects of stromal cells. For IRDS-Rs, treatment with the GSI
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Figure 5. Stromal Cells Drive the Expansion of a Subpopulation of Therapy-Resistant Breast Cancer Cells through Antiviral STAT1 and
NOTCH3 Signaling
(A) Gene Set Analysis comparing IRDS-R in monoculture versus coculture with MRC5 fibroblasts or comparing 1833 IRDS-R in coculture transfected with si-
STAT1 versus siControl.
(B) Percentage of CD44+CD24low+ 1833 IRDS-R after coculture with MRC5. All CD24low+ cells are also CD44+.
(C–E) (C) Survival of sorted CD44+CD24low+ and CD44+CD24neg cells after 10 Gy RT or 4 mMdoxorubicin (chemo). Number of mammospheres from 1833 IRDS-R
after (D) coculture or (E) coculture following knockdown of STAT1 (siS1), NOTCH3 (siN3), or control (siCt) or after treatment with the GSI DAPT.
(F) Number of mammospheres after NICD3 induction by doxycycline in monoculture.
(G–K) (G) Proportion of surviving mammospheres relative to untreated control in mono- or coculture after 3 Gy RT. Cell death after 10 Gy RT following (H)
knockdown of NOTCH3 in 1833 IRDS-R, (I) knockdown of JAG1 in 1833 IRDS-R, MRC5 (Stroma), or both (n = 4); (J) expression of NICD3 (n = 7); or (K) STAT1
knockdown with and without NICD3 expression (n = 3–4).
(L) Cell death of IRDS-Rs and IRDS-NRs after 10 Gy RT and treatment with the GSI DAPT or DMSO (n = 5–10).
(M) Photon flux from mice xenografted subcutaneously with luciferase-labeled 1833 IRDS-R with or without MRC5 fibroblasts (Stroma) and treated 7 days later
with 8 Gy RT, the GSI DAPT, both, or untreated. Mean values (black ‘‘X’’) are connected by blue line. Representative tumors after treatment are inset. In presence
of stroma, tumor response was associated with RT (p < 0.001) and GSI (p = 0.004). Without stroma, RT (p = 0.019), but not GSI (p = 0.79), was associated with
response.
(N) Percentage of CD44+CD24low+ cells in tumors from mice xenografted with 1833 IRDS-R with and without MRC5 stroma 7 days after the indicated treatment.
(O) Survival of these mice, which are independent cohorts from that used in Figure 5M. *p < 0.05.
Unless noted, all bar plots in figure are mean ± SD of n biological replicates. See also Figure S5.DAPT completely or partially reversed the protective effects of fi-
broblasts and had only small effects in monoculture (Figure 5L).
In contrast, for IRDS-NRs, neither coculture nor GSI discernibly
affected cytotoxicity after RT. In vivo, admixing fibroblasts with
luciferase-labeled 1833 IRDS-R resulted in the upregulation ofNOTCH targets (Figure S5I). Treatment with GSI alone
decreased NOTCH targets (Figure S5J) but had only a mild or
insignificant effect on breast cancer growth in the presence
(p = 0.083) or absence (p = 0.67) of admixed fibroblasts (Fig-
ure 5M). With RT, the presence of fibroblasts protected breastCell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 507
cancer (p = 0.026); however, three consecutive doses of GSI
starting from the day of RT reversed this protection. Moreover,
GSI prevented the in vivo enrichment of CD44+CD24low+ TRCs
observed after RT (Figure 5N), and the combination of RT and
GSI rendered nearly 30% of mice tumor free, as compared to
0% with RT or GSI alone (Figure 5O). Thus, for IRDS-R basal-
like breast cancers, the combination of GSI and genotoxic ther-
apy prevents stroma-mediated expansion of TRCs adept at
tumor reinitiation.
Expression of Antiviral and NOTCH3 Pathways in
Primary Human and Mouse Basal-like Breast Cancer
To investigate potential disease relevance, we examined
whether basal subtype primary human breast cancers show
expression and activation of antiviral/NOTCH3 pathways in
ways predicted by our experimental models. We first analyzed
protein expression of RAB27B, STAT1, and NOTCH3 in primary
human triple-negative breast cancers (TNBC), which overlap
with the basal subtype. RAB27B showed strong stromal staining
in 71%of TNBC tumors (Figure 6A). By image analysis, the inten-
sity of STAT1 preferentially exhibited a strong tumor-stroma
border pattern also in 71% of TNBC samples. For NOTCH3,
this tumor-stroma border pattern was more subtle, possibly
because NOTCH3 and JAG1 are themselves NOTCH targets,
but was discernible in 29% of TNBC cases. Examination of tu-
mors from TNBC patient-derived xenografts (PDX) also demon-
strated strong tumor-stroma border patterns for STAT1 and
NOTCH3 (Figure 6B). Moreover, breast tumors from the
K14cre;BRCA1F/F;p53F/F mice, which are a model of basal sub-
type breast cancer (Liu et al., 2007), revealed patterns of staining
similar to primary human TNBC (Figure 6B). In contrast, a distinct
tumor-stromaborder patternwas rarely observed in ER+ primary
tumors for either STAT1 (14%) or NOTCH3 (0%) and was not
observed in ER+ PDX tumors (Figure S6A). Thus, in both human
and mouse basal-like tumors, key drivers of anti-viral/NOTCH3
signaling can show preferential localization around sites of tu-
mor-stroma interaction.
To investigate whether similarities in localization of antiviral
and NOTCH3 proteins between in vivo tumors and in vitro
models are accompanied by expected gene expression
changes in IRDS and NOTCH target genes, we used three
distinct sets of gene expression data from primary human breast
cancer. The Stroma series is a 53-sample set of breast cancer
stroma and adjacent normal stroma, the NKI295 series is
composed of 295 primary human breast tumors confirmed to
be largely cancer cells, and the LCMD series contains 28 paired
primary tumor and stroma samples that were separated by
laser-capture microdissection. Consistent with breast cancer
inducing stromal RAB27B, the Stroma series revealed higher
RAB27B expression in tumor stroma compared to adjacent
normal, whereas other RABs on average had similar or
decreased expression (Figure 6C). Using the NKI295 series,
RIG-I was the best predictor of IRDS status compared to other
PRRs and interferon-related genes (Figure 6D). Of all available
NOTCH family receptors and ligands on the LCMD series array
(Figure 6E), breast cancer NOTCH3 and stromal JAG1 were
the best at predicting expression of breast cancer NOTCH tar-
gets (Table S4) as measured by their average expression (meta-508 Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc.gene). Moreover, when breast cancer NOTCH3 was paired with
breast cancer RIG-I, and stromal JAG1 was paired with stromal
RAB27B, high expression of the two pairs cooperatively pre-
dicted high NOTCH metagene expression (Figures S6B and
S6C). In total, these data indicate that gene expression changes
attributed to the antiviral and NOTCH3 pathways can be
observed in primary tumors.
Because STAT1 enhances the transcriptional response to
NOTCH3 in IRDS-R breast cancer, high NOTCH target gene
expression is expected to associate with high NOTCH3/JAG1
and high STAT1 activity in basal subtype tumors. To examine
this, we used the NKI295 series and substituted stromal
JAG1 with breast cancer JAG1, as stromal genes cannot be
evaluated and breast cancer JAG1 was comparable to
stromal JAG1 at predicting NOTCH target gene expression
(Figure S6D). For STAT1 activity, we used the clinical IRDS
classifier because it includes STAT1, and STAT1 both regulates
(Figure 1H) and correlates with IRDS status (Spearman’s corre-
lation coefficient 0.79, p < 0.001). As expected, increasing
NOTCH3 resulted in higher likelihood of NOTCH pathway acti-
vation (Figure 7A). The probability was highest when NOTCH3,
JAG1, and IRDS were all high, particularly for basal subtype tu-
mors (red dots, top right plot), a result that was recapitulated in
basal-like tumors from the K14cre;BRCA1F/F;p53F/F mouse
model (Figure 7B). Thus, these results suggest that antiviral
signaling preferentially facilitates the transcriptional response
to NOTCH3 in primary human and mouse basal subtype
tumors.
Antiviral/NOTCH3 Pathway Genes Predict Clinical
Resistance to Chemotherapy and RT
Having shown that NOTCH3 and the IRDS contribute to predict-
ing NOTCH activation in the NKI295 series, we examined
whether both pathways function together to predict clinical
resistance to chemotherapy and RT. NOTCH3 was dichoto-
mized using a mean cut-point, and for consistency, IRDS status
was defined using our original seven gene clinical classifier.
Interestingly, 31% of NOTCH3(hi)/IRDS(+) tumors belonged to
either the basal or claudin-low subtype (Figure 7C; p < 0.01 by
chi-square test), two basal-like subtypes that are enriched in
cancer stem-cell-like features (Prat et al., 2010). Consistent
with this, NOTCH3(hi)/IRDS(+) tumors showed enrichment of
the same breast cancer TIC signature upregulated in IRDS-R
cells after coculture (Figures 7C and 5A), suggesting that these
tumors could also contain TRCs. Indeed, among the patients
who received chemotherapy, those with the highest risk of
breast-cancer-specific death were NOTCH3(hi)/IRDS(+) (Fig-
ure 7D). Cox regression using continuous values rather than arbi-
trary cut-offs for NOTCH3 demonstrated that higher NOTCH3
augmented risk only among patients with tumors that were
IRDS(+) and/or basal subtype (Figure 7E). The effect of both
pathways on survival was distinct from metastasis risk as both
were independent of the MammaPrint metastasis signature
(van de Vijver et al., 2002), and neither were predictive among
patients not receiving chemotherapy (Figure S7A). NOTCH3
(hi)/IRDS(+) patients were also the most likely to fail RT (Fig-
ure 7F). Finally, using the Stroma series, we found that high
stromal RAB27B predicted poor survival, whereas other RABs
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Figure 6. Expression of Antiviral and NOTCH3 Pathway Predicts IRDS and NOTCH Target Gene Expression in Primary Human and Mouse
Tumors
(A and B) (A) Expression of RAB27B, STAT1, and NOTCH3 in primary human triple-negative breast cancer (TNBC) or (B) in TNBC patient-derived xenografts (PDX)
and basal-like tumors from K14Cre;BRCA1F/F;p53F/F conditional knockout mice. Arrows show representative areas of stroma. Insets for TNBC images show
darker staining regions (red) segmented from lighter regions. Semiquantitation of expression in stroma (S), tumor (T), or tumor-stroma borders (B) is indicated.
Vertical bar is 200 microns. A total of seven primary TNBC tumors were scored. Two out of two PDX and three out of three mouse tumors gave similar results.
Shown are representative images and semiquantitation.
(C) Box-and-whisker plots of expression values for the indicated RABs from primary human breast cancer stroma (Tumor) or normal stroma (Norm) using the
stroma series.
(D) Importance scores (higher is more predictive) from a RF regression model (variance explained: 55.1%) to predict breast cancer IRDS expression using the
NKI295 series. Adjusted effect of RIG-I on IRDS expression (right).
(E) Heat map and scale showing expression of all available NOTCH receptors in breast cancer (brown) and NOTCH ligands in stroma (green) from the LCMD
series. These were used to predict the average expression of NOTCH target genes in breast cancer (variance explained: 30.2% ± 1.1%) defined by GSI washout
(NOTCH Meta). On the right are importance scores from Monte Carlo replications.
See also Figure S6.showed no association (Figures 7G and S7B). In total, the anti-
viral/NOTCH3 pathways predict clinical resistance, particularly
for basal subtype tumors.
DISCUSSION
We demonstrate that interaction of stromal cells with breast
cancer cells results in paracrine and juxtacrine signaling events
to drive stroma-mediated resistance (Figure 7H). First, stromalcells increase RAB27B and transfer 50-triphosphate RNA in
exosomes to activate RIG-I antiviral signaling in breast cancer
cells. Second, breast cancer cells induce NOTCH3 to make
the receptor available for engagement with JAG1. The para-
crine and juxtacrine pathways converge as STAT1 facilitates
the transcriptional response to NOTCH3, resulting in the expan-
sion of therapy-resistant TICs. Consistent with this, stromal
cells mediate both decreased cell death and continued tumor
growth after RT. Blocking the NOTCH pathway resensitizesCell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 509
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Figure 7. NOTCH3 and STAT1/IRDS Cooperate to Predict NOTCH Target Genes and Clinical Resistance to Chemotherapy and RT Prefer-
entially in Basal-like Breast Cancers
(A and B) Prediction of NOTCH target gene expression by IRDS and NOTCH3/JAG1 in (A) primary human tumors and in (B) basal-like tumors from the
K14Cre;BRCA1F/F;p53F/F conditional knockout mice. For human tumor analysis, the NKI295 series was used. The probability of NOTCH pathway activation as
measured by the NOTCH metagene is shown on the y axis with probabilities for basal (red dots) or nonbasal (blue dots) tumors displayed separately. The
percentage of tumors with greater than 80% probability of NOTCH activation is inset. A LOWESS regression line (black dashed line) is shown. IRDS and JAG1
were equally divided into low, intermediate, and high values. For mouse tumor analysis, IRDS, NOTCH3, and JAG1 expression were dichotomized into only high
and low due to smaller sample size. Mean value is marked by red line.
(C) Heat map showing probabilities of NOTCH activation and NOTCH3 expression for each patient (columns) in the NKI295 series. All values are scaled between
0 and 1. Hatches below the heat map show status for IRDS(+), NOTCH3(hi), and the indicated molecular subtypes. On the right is Gene Set Analysis for the same
TIC signature used in Figure 5A and compares NOTCH3(hi)/IRDS(+) tumors to those that are NOTCH3(lo) and/or IRDS().
(D) Survival after adjuvant chemotherapy of patients from the NKI295 series stratified by NOTCH3 and IRDS. Overall p value is shown.
(E) Hazard ratios and 95% confidence intervals from Cox regression analysis for breast cancer survival using NOTCH3 as a continuous variable, IRDS status
(positive versus negative), and MammaPrint (Mamma) metastasis signature status (positive versus negative). All patients received adjuvant chemotherapy.
Hazard ratio forNOTCH3 is per unit increase in expression. Analyses are also stratified by IRDS status and basal versus nonbasal subtype tumors. Values are not
shown if there are too few patients in the group.
(F) Relapse in irradiated region (local-regional control) after adjuvant RT.
(G) Hazard ratio from Cox regression for relapse in the Stroma series using stromal RAB27B as a continuous variable.
(H) Model of the tumor-stroma antiviral/NOTH3 pathways controlling RT/chemo resistance.
See also Figure S7.tumors to RT, rendering mice tumor free. These biological inter-
actions between antiviral and NOTCH3 signaling are mirrored
by statistical evidence that they jointly influence NOTCH acti-
vation and treatment resistance in primary human basal-like
breast cancers.510 Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc.The role of exosomes in cancer as mediators of cell-cell
communication with the microenvironment has gained in-
creasing attention. Functionally, exosomes have intriguing and
elaborate roles in cancer progression and can transfer a variety
of proteins, DNA, and RNA that can explain some of their effects
(Peinado et al., 2012; Valadi et al., 2007). Our data suggest
that RNA contained within exosomes is enriched in noncoding
transcripts and can activate RIG-I. Consistent with the known
properties of RIG-I stimulatory viral RNA (Loo and Gale, 2011),
50-triphosphate is similarly required for exoRNA to activate
RIG-I. Sequencing exoRNA revealed no evidence of viral tran-
scripts—rather, exoRNA was enriched in transposable elements
and other repetitive sequences, many of which are known or
putative RNA polymerase III transcripts. RNApolymerase III tran-
scripts can contain 50-triphosphate and likely are largely non-
coding (Dieci et al., 2013). Although the quantity and diversity
of noncoding human transcripts is large (ENCODE Project Con-
sortium, 2012) and RIG-I is not known to overtly show sequence-
specific binding, the enrichment for transposable elements and
other repetitive elements in exosomes is interesting given the
viral origins of some of these sequences (Belancio et al., 2010).
Despite prolific incorporation into the genome, it is notable that
these elements are normally transcriptionally silenced but can
be derepressed to high levels in cancer (Ting et al., 2011).
When expressed, these elements can also exhibit subcellular
partitioning into the nucleus and the cytoplasm (Goodier et al.,
2010). Accumulation of transposable elements can result in
autoimmunity with elevated ISGs in normal tissue (Stetson
et al., 2008). Thus, our results suggest that noncoding RNA found
in exosomes and similar microvesicles (Balaj et al., 2011; Li et al.,
2013a) may coax antiviral responses to influence treatment
resistance, potentially adding to the increasing evidence that
atypical RNA transcripts can contribute to human disease.
Both antiviral/interferon signaling and the NOTCH pathway are
known to regulate the maintenance of normal and cancer stem-
like cells. Interestingly, inflammatory/stress signaling involving
STAT can function with NOTCH signaling in development and
in homeostasis to influence self-renewal (Kux and Pitsouli,
2014). For example, in Drosophila, inflammation and stress in
the midgut leads to compensatory intestinal stem cell prolifera-
tion that is regulated by STAT. STAT can be activated non-cell-
autonomously by damaged cells, while distinct levels of NOTCH
control intestinal stem cell commitment and differentiation. Our
findings that stromal fibroblasts can secrete exosomes to induce
antiviral signaling in breast cancer cells and that STAT1 pro-
motes NOTCH3-driven expansion of therapy resistant TICs high-
light an unexpected way that these two evolutionarily conserved
pathways converge to influence cell fate in cancer.
The mechanisms whereby basal-like tumors are preferentially
protected by stroma through antiviral/NOTCH3 signaling require
further investigation. One mechanism indicated herein may be
the capacity of basal-like breast cancer cells to coerce stromal
cells to augment exosome secretion. RAB27B is uniquely
induced in stromal cells by IRDS-R but not IRDS-NR breast
cancer, and evidence from primary human tumors also distin-
guishes it from other RABs. However, alternative methods to
either increase exosome production in the microenvironment
or instigate similar antiviral signaling (e.g., immune cells) may
also exist. Other factors that might contribute to differences in
the way basal-like tumors respond to stroma include defects in
the BRCA1 pathway, which have been associated with basal
and claudin-low tumors (Prat et al., 2010). It is notable that two
of the IRDS-R breast cancer cell lines have reported mutationsin BRCA1 (Elstrodt et al., 2006), and BRCA1 null mouse mam-
mary tumors show evidence for the antiviral/NOTCH3 pathway.
As a cell extrinsic mechanism of resistance, the protective effect
of stroma may be critical for certain breast cancers with intrinsic
DNA damage sensitivity.
Extrapolating the relevance of findings frommodel systems to
human disease is often challenging. In this study, extensive sta-
tistical modeling of primary tumor expression data was used to
support the mechanisms dissected from experimental models.
Specifically, primary tumor data suggest that (1) RIG-I is a driver
of the IRDS, (2) breast cancer NOTCH3 and stromal JAG1 are
important regulators of NOTCH target gene expression, (3)
NOTCH3 and STAT1 are localized to sites of tumor-stroma inter-
action, (4) STAT1 facilitates the transcriptional response to
NOTCH3, (5) IRDS/STAT1 and NOTCH3 identify patients with
both high NOTCH target genes and chemo/RT resistant tumors,
and (6) high IRDS/NOTCH3 is preferentially observed in basal
and claudin-low subtype primary tumors, which are known to
be enriched in cancer stem-cell-like features (Prat et al., 2010).
These observations, combined with preclinical studies showing
that GSI can reverse the effects of stromal cells on TRC expan-
sion, tumor growth after genotoxic damage, and survival sug-
gest the disease relevance of our findings. Together, the antiviral
and NOTCH3 pathways may serve as companion biomarkers
and druggable targets for stroma-mediated resistance.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell Death Assays
Breast cancer and stromal cell lines used in this study are listed in Table S1.
For cocultures, breast cancer cells were labeled with CFSE and mixed 1:1
with stromal cells, typically MRC5 fibroblasts unless otherwise noted. CM
was harvested at 48 hr from subconfluent cultures and added directly for
24–48 hr. CM from monoculture was used as a control. For cell death assays,
mono- or cocultures were irradiated at 48 hr with 10 Gy. Cell death of CFSE-
labeled breast cancer cells was measured at 96 hr post-RT by flow cytometry
using Sytox-Red. For GSI treatment, 10 mMDAPT or DMSO control was used.
Exosome Isolation and Analysis
Cells were grown in exosome-depleted media, and exosomes were isolated
from CM collected at 48 hr by serial centrifugation. For exosome assays, an
equal volume of exosomes was added to cells for 24–48 hr. For exosome
depletion, CM was ultracentrifuged overnight. Dye transfer was visualized by
microscopy or by flow cytometry at 24 hr. ExoRNA was extracted after 48 hr
of culture using TRIzol. Assays were performed at 16–24 hr after transfection
of 10–100 ng exoRNA using RNAiMax.
Chromatin Immunoprecipitation and Primary Transcript Analysis
Breast cancer cells were cocultured with MRC5 fibroblasts or treated with CM
for 48 hr. NICD3 was induced with 0.1 mg/ml doxycycline for 72 hr.
Mammosphere Analysis
CFSE-labeled breast cancer cells cultured with or without MRC5 fibroblasts
were sorted by FACS. siRNA knockdown was performed 1 day before cocul-
ture, and doxycycline was added for 1 week to induce NICD3. Cells were
seeded at 10,000 per well. After 7 days, spheres larger than 100 mm were
counted.
In Vivo Mouse Studies
1 3 106 MDA-MB-231 1833 cells with and without an equal number of MRC5
fibroblasts were injected with Matrigel into the flanks of 6- to 8-week-old
female nude mice. Starting at day 7, tumors were irradiated with 8 Gy, and
mice were treated with three daily doses of DAPT at 10 mg/kg.Cell 159, 499–513, October 23, 2014 ª2014 Elsevier Inc. 511
Statistical Analysis and Computational Modeling
Unless otherwise noted, results reported are mean ± SD of n independent
biological replicates. For comparisons of the mean between two groups, a
two-tailed two-sample t test was employed. Genes upregulated from tran-
scriptomic analysis of tumor-stromal cell interaction are listed in Tables S2,
S3, and S5. NOTCH targets and IRDS genes used in computational studies
are listed in Tables S4 and S6.
ACCESSION NUMBERS
The GEO accession number for the expression and sequencing data reported
in this paper is GSE60998.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2014.09.051.
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